Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.56 (
caspase-3
)
35,750
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nasopharyngeal carcinoma (NPC) is one of the most prevalent forms of highly invasive malignancy in Southern China and Southeast Asia. The pathogenesis of NPC is a multistep process driven by the acquisition of numerous genetic abnormalities. We investigated the potential oncogenic role of the Rho-guanine nucleotide exchange factor 3 gene,
ARHGEF3
, in NPC pathogenesis. Expression levels of
ARHGEF3
were frequently up-regulated in NPC cell lines and tissues. In a large cohort of clinical NPC tissues high expression of
ARHGEF3
was positively associated with an increased T status, distant metastasis, and a more advanced clinical stage (P < 0.05). Survival analysis revealed that
ARHGEF3
expression was a significant and independent prognosis factor for NPC patients. In NPC cell lines, knockdown of
ARHGEF3
was sufficient to inhibit cell growth, motility, and invasion in vitro, whereas ectopic overexpression of
ARHGEF3
substantially enhanced NPC cells tumorigenesis and metastasis in vivo. Depletion of
ARHGEF3
in NPC cells dramatically promoted
caspase-3
induced apoptosis and an anti-apoptosis factor, BIRC8, was identified as a critical downstream target of the
ARHGEF3
. Our findings suggest that increased expression of
ARHGEF3
plays a critical oncogenic role in NPC pathogenesis by preventing cell apoptosis through the up-regulation of BIRC8, and
ARHGEF3
might be employed as a novel prognostic marker and effective therapeutic target for human NPC.
...
PMID:The putative tumor activator ARHGEF3 promotes nasopharyngeal carcinoma cell pathogenesis by inhibiting cellular apoptosis. 2702 92
